OECD Home › Directorate for Financial and Enterprise Affairs › Competition › Publications & Documents
Publications & Documents
The 2014 OECD-IDB Latin American Competition Forum takes place in Montevideo, Uruguay, on 16-17 September. Discussions will focus on electricity markets in Latin America, a peer review of Costa Rica's competition law and policy and mainstreaming competition policy with key policy makers.
We are looking for new and interesting thinking on how policy options in the areas of competition, corporate governance, capital markets and financial services, international investment and foreign bribery can have an impact on our well-being as defined by the OECD's Better Life Initiative.
Merger control constitutes an essential component of an effective competition system. This in-depth study of Chile’s merger control regime assesses the main existing issues in the current system and provides suggestions for improvement based on OECD and international standards.
El control de concentraciones constituye un componente esencial de un sistema de competencia eficaz. El estudio evalúa los principales problemas del régimen de control de concentraciones vigente en Chile y propone recomendaciones para su mejora de conformidad con los estándares de la OCDE y las mejores prácticas internacionales.
This page contains information on the work of the OECD and Chile in the area of Competition Law and Policy.
This page contains information on the work of the OECD and Mexico in the area of Competition Law and Policy.
This page contains information on the work of the OECD and Colombia in the area of Competition Law and Policy.
Cartel enforcement can be extremely challenging and proactive detection tools such as screening can be very helpful to competition authorities. This page presents the work by the OECD Competition Committee in this area and provides links to key documents and related material.
View the most recent issue of the Newsletter from the OECD-GVH Regional Centre for Competition in Budapest.
Entry by generic pharmaceuticals can enhance competition, but innovation should be, at the same time, enhanced by allowing innovators to obtain intellectual property rights on their originator drug. The Competition Committee discussed these issues in June 2014.